[
    [
        {
            "time": "2018-12-14",
            "original_text": "Health Care Sector Update for 12/14/2018: JNJ, KANG, AXON, PFE, ABT, MRK, AMGN",
            "features": {
                "keywords": [
                    "sector update",
                    "health care",
                    "JNJ",
                    "PFE",
                    "ABT"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "health care"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 9,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2018-12-14",
            "original_text": "Daily Dividend Report: NLY, ABT, PFE, T, EQR",
            "features": {
                "keywords": [
                    "dividend report",
                    "NLY",
                    "ABT",
                    "PFE"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "dividends"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 2,
                "Headline_Structure": 5,
                "Source_Recency": 3
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "Pfizer Boosts Q1 Dividend, Launches $10 Billion Buyback as Read Says Farewell",
            "features": {
                "keywords": [
                    "dividend boost",
                    "buyback",
                    "Pfizer"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 4,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "Pfizer's cut-price version of Avastin wins EU panel greenlight",
            "features": {
                "keywords": [
                    "cut-price",
                    "Avastin",
                    "EU greenlight",
                    "Pfizer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "Pfizer Declares First-Quarter 2019 Dividend",
            "features": {
                "keywords": [
                    "first-quarter dividend",
                    "Pfizer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 5,
                "Duration": 3,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEVâ„¢ (bevacizumab)",
            "features": {
                "keywords": [
                    "CHMP opinion",
                    "oncology biosimilar",
                    "ZIRABEV",
                    "Pfizer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "Merck bolsters animal health unit with $2.4 bln Antelliq purchase",
            "features": {
                "keywords": [
                    "animal health",
                    "Antelliq",
                    "purchase",
                    "Merck"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 3,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        },
        {
            "time": "2019-03-05",
            "original_text": "Pfizer Initiates Phase 3 Program for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older",
            "features": {
                "keywords": [
                    "Phase 3 program",
                    "vaccine",
                    "Pfizer"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]